Michael Meyers, MD, PhD
Dr. Michael Meyers is a medical oncologist and experienced drug developer who has contributed to the successful development and commercialization of multiple new therapies. Michael has served as a Senior Clinical Advisor at Nuvalent since 2020 and was involved in the design of the ongoing Phase 1/2 trials for its parallel lead programs in NSCLC.
Most recently, Michael served as the Senior Vice President, Chief Development Officer and Chief Medical Officer at Syndax Pharmaceuticals from 2015 until March 2022, where he led the development of multiple molecules in breast cancer, various immune-oncology indications, acute leukemias, and chronic Graft versus Host Disease.
Prior to joining Syndax, he held a number of senior R&D roles at Johnson & Johnson, including serving as Vice President, GU Oncology, Compound and Clinical Leader, and as Vice President, Oncology Scientific Innovation in Johnson and Johnson’s London Innovation Centre. Michael also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc and worked in oncology clinical development at the Schering-Plough Research Institute. Prior, he was on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma.
He received his MD and his PhD in Microbiology and Immunology from Albert Einstein College of Medicine in New York and was elected to Alpha Omega Alpha (the medical school honor society). He completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship, where he served as Chief Fellow in Medical Oncology, at Memorial Sloan Kettering Cancer Center.